siponimod
siponimod: developed by 1 company · 3 clinical trials tracked · 1 FDA decision.
siponimod evidence translation
What we can confirm
1 FDA record · 3 tracked trials
What it means
What to watch
Prepared research question
How could siponimod → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Novartis AG (NVS) Multiple Sclerosis (MS) | Phase 3 |
Clinical Trials (3)
SIPO1-AD: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients With Mild Alzheimer's Disease
Primary endpoint: Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs)
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension
Primary endpoint: Annualized relapse rate (ARR) in target pediatric participants
Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Primary endpoint: Number of Major Congenital Malformations (MCMs)
Frequently asked questions
Who is developing siponimod?
siponimod is being developed by Novartis AG.
How many clinical trials involve siponimod?
BioSniper tracks 3 clinical trials involving siponimod.
What is siponimod's latest FDA decision?
The most recent tracked FDA decision for siponimod is Approval, dated March 26, 2019.